An Areva subsidiary is to build a new facility to produce medical-grade lead-212 for anticancer treatments. The facility, to be located at Areva Med’s Bessines site in western France, is scheduled to open in 2013.
Areva CEO Anne Lauvergeon said: “This project illustrates Areva’s capacity for innovation. We are delighted to contribute to the development of innovative medical solutions thanks to our core business activities.”
Lead-212 is used in innovative alpha radio-immunotherapy to combat cancer.
Related ArticlesVT Nuclear Services secures UK contracts Dissolution solution